Intravitreal Injectable Market is segmented By Drug Class (Anti-VEGF, Steroids, Antibiotics, Antifungals, Antivirals), By Indication (Diabetic Retinopathy, Macular Degeneration, Endophthalmitis, Retinal Vein Occlusions, Others)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

[150 Pages Report] Intravitreal Injectable Market size was valued around US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.8% during the forecast period (2023-2030). Intravitreal injection is used to place medication directly in the space back of the eye in the vitreous cavity, which is filled with a fluid called the vitreous humor gel. The anti-VEGF drugs and steroids help to reduce fluid leakage related to these disorders. Antibiotic, antifungal and antiviral drugs are also used to treat patients with eye infections, such as retinitis and endophthalmitis. In some cases, an injection is used to insert a small gas bubble to aid in repairing a retinal detachment. Moreover, intravitreal injection is an effective treatment for retinal diseases, such as diabetic retinopathy, macular degeneration, endophthalmitis, and retinal vein occlusion.

Intravitreal Injectable Market - Strategic Insights

Metrics	Details
Market CAGR	5.8%
Segments Covered	By Drug Class, By Indication, By Distribution Channel, and By Region
Report Insights Covered	Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region	Asia Pacific
Largest Market Share	North America

To Get a Free Sample Click here

Market Dynamics

Growing chronic retinal diseases and key manufacturers focusing on developing new drugs to meet patients' needs are the factors driving the market in the forecast period.

The increasing prevalence of cataracts worldwide is expected to drive market growth.

According to the World Health Organization, in 2021, cataracts are the primary cause of blindness worldwide, accounting for nearly 51% of all cases. It is anticipated that by 80 years of age, more than half of all Americans will either have a cataract or have surgery to correct the problem. Moreover, the data published by the National Eye Institute shows that after the age of 40, every decade of life brings a higher chance of developing the condition. Cataract risk is significantly higher in women. The condition affects around 61 percent of women, as opposed to 39 percent of men. Therefore, intravitreal injection of antibiotics and steroids is part of routine cataract surgery. Thus, there is an increase in the adoption of intravitreal injectables worldwide.

Risks associated with the Intravitreal injections are expected to hamper the market growth.

The risks of intravitreal injections include the following, Pain/phantom limb sensation/epiphora possibly due to dry eye, corneal abrasion, infection, Bleeding (subconjunctival, vitreous hemorrhage) (subconjunctival, vitreous hemorrhage), Tear or detachment of the retina Cataract (by accidentally striking the lens), infection (endophthalmitis), Uveitis/vasculitis of the retina (higher risk with brolucizumab), Visual impairment, Eye loss due to severe infection and increased intraocular pressure with optic nerve damage primarily with steroids but may also occur after higher numbers of anti-VEGF injections.

COVID-19 Impact Analysis

The coronavirus pandemic has challenged the world's healthcare system with unprecedented challenges and uncertainty. Hospitals have undertaken significant staff rearrangement since the pandemic breakout to prepare for the upcoming COVID-19 patient surge. Non-urgent surgical activities and outpatient visits were drastically reduced, resulting in treatment suspensions and postponements. Intravitreal injection (IVI) of antivascular endothelial growth factors (VEGFs) or steroids is a frequent intraocular technique that improves patients' visual acuity and slows the progression of certain retinal illnesses. During the pandemic, however, there was a considerable decline in clinic visits for IVI in several countries. In the subset of patients who require regular injections, such failure to follow up may result in irreversible vision damage. The American Society of Retina Specialists (ASRS) recommended IVI as essential among all surgeries and procedures for retinal diseases.

Additionally, ophthalmologists struggled to deliver the best treatment plan because the group of patients requiring IVI, which includes the elderly and those with diabetes, overlaps significantly with the group of patients with increased COVID-19 mortality. However, delaying therapy may put these patients at risk of lifelong vision loss. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually during the forecast period.

Segment Analysis

Anti-VEGF segment is expected to hold the largest market share in intravitreal injectable

The anti-VEGF segment accounted for the largest market share in 2021. The segment benefits because anti-VEGF drugs have proven safe for intraocular use as they reduce fluid leakage in case of eye disorders. Its superior features, such as excellent biocompatibility and impressive pharmacodynamic properties, have increased its popularity among ophthalmologists worldwide. Anti-VEGF drugs mostly target chronic retinal diseases, such as diabetic retinopathy, macular degeneration, retinal vein occlusion, and others. For instance, Genentech USA, Inc., Ranibizumab (Lucentis) is in a class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It is used to treat wet age-related macular degeneration, an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities. Therefore, it has increased the demand for anti-VEGF intravitreal injections. Thus, from the above factors, the market segment is accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global intravitreal injectable

North America region is accounted for the largest market share in 2021. The increasing prevalence of eye disorders, the growing geriatric population, and rising FDA approvals for the products are some of the factors driving the market in the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2020, the prevalence is estimated that 1.8 million Americans aged 40 years and older are affected by Age-related Macular Degeneration (AMD), and an additional 7.3 million with large drusen are at substantial risk of developing AMD. The number of people with AMD reached 2.95 million in 2020. AMD is the leading cause of permanent impairment of reading and fine or close-up vision among people aged 65.

Moreover, on October 22, 2021, Roche announced that the U.S. Food and Drug Administration had approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or wet age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Thus, from the above factors, the North America region is accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the intravitreal injectable market are Alcon Pharmaceuticals, Valeant Pharmaceuticals International, Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Novartis AG, Allergan, Alimera Sciences, ThromboGenics, Inc., Bristol-Myers Squibb Company and Bausch & Lomb.

For Instance, on October 25, 2021, Bausch + Lomb and Clearside Biomedical, Inc. announced that the FDA had approved triamcinolone acetonide injectable suspension (XIPERE) for suprachoroidal usage in the treatment of macular edema associated with uveitis, another type of eye inflammation.

Novartis AG:

Overview:

Novartis AG is a multinational pharmaceutical company based in Basel, Switzerland. The company engages in developing, manufacturing, and marketing healthcare products. It operates the following segments such as Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develop, manufactures, distributes and sells patented pharmaceuticals and comprises two business units: Novartis Oncology and Novartis Pharmaceuticals. Business segment such as Innovative Medicines, includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments. The Sandoz segment develops, manufactures and markets finished dosage form medicines and intermediary products, including active pharmaceutical ingredients.

Product Portfolio:

Lucentis (ranibizumab): Ranibizumab injection products are used to treat wet AMD, an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities.

The global intravitreal injectable report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Intravitreal Injectable Market